NCT00192192View on ClinicalTrials.gov

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2000

Study Completion Date

December 31, 2000

Conditions

Influenza

Interventions

BIOLOGICAL

CAIV-T

Trial Locations (1)

06904

Stamford Hospital, Stamford

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192192 - Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults | Biotech Hunter | Biotech Hunter